245 related articles for article (PubMed ID: 16352927)
1. [Gene therapy and molecular therapeutic for head and neck cancer].
Tanaka H
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2046-51. PubMed ID: 16352927
[TBL] [Abstract][Full Text] [Related]
2. Novel adenoviral gene delivery system targeted against head and neck cancer.
Li D; Guang W; Abuzeid WM; Roy S; Gao GP; Sauk JJ; O'Malley BW
Laryngoscope; 2008 Apr; 118(4):650-8. PubMed ID: 18176343
[TBL] [Abstract][Full Text] [Related]
3. A replication-selective adenoviral vector for head and neck cancers.
Tanaka H; Shirakawa T; Zhang Z; Hamada K; Gotoh A; Nibu K
Arch Otolaryngol Head Neck Surg; 2005 Jul; 131(7):630-4. PubMed ID: 16027288
[TBL] [Abstract][Full Text] [Related]
4. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
Nemunaitis J; Ganly I; Khuri F; Arseneau J; Kuhn J; McCarty T; Landers S; Maples P; Romel L; Randlev B; Reid T; Kaye S; Kirn D
Cancer Res; 2000 Nov; 60(22):6359-66. PubMed ID: 11103798
[TBL] [Abstract][Full Text] [Related]
5. FasL gene therapy: a new therapeutic modality for head and neck cancer.
ElOjeimy S; McKillop JC; El-Zawahry AM; Holman DH; Liu X; Schwartz DA; Day TA; Dong JY; Norris JS
Cancer Gene Ther; 2006 Aug; 13(8):739-45. PubMed ID: 16543918
[TBL] [Abstract][Full Text] [Related]
6. Current role of gene therapy in head and neck cancer.
Ganly I; Soutar DS; Kaye SB
Eur J Surg Oncol; 2000 Jun; 26(4):338-43. PubMed ID: 10873352
[TBL] [Abstract][Full Text] [Related]
7. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma.
Clayman GL; el-Naggar AK; Roth JA; Zhang WW; Goepfert H; Taylor DL; Liu TJ
Cancer Res; 1995 Jan; 55(1):1-6. PubMed ID: 7805018
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region.
Edelman J; Edelman J; Nemunaitis J
Curr Opin Mol Ther; 2003 Dec; 5(6):611-7. PubMed ID: 14755887
[TBL] [Abstract][Full Text] [Related]
9. Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus.
Suominen E; Toivonen R; Grenman R; Savontaus M
J Gene Med; 2006 Oct; 8(10):1223-31. PubMed ID: 16941521
[TBL] [Abstract][Full Text] [Related]
10. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.
Zhu ZB; Mathis JM; Makhija SK; Lu B; Wang M; Ji S; Rivera AA; Rosenthal EL; Siegal GP; Curiel DT
Int J Oncol; 2007 Nov; 31(5):1213-22. PubMed ID: 17912450
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of topical gene therapy for head and neck squamous cell carcinoma in an organotypic model.
Eicher SA; Clayman GL; Liu TJ; Shillitoe EJ; Storthz KA; Roth JA; Lotan R
Clin Cancer Res; 1996 Oct; 2(10):1659-64. PubMed ID: 9816113
[TBL] [Abstract][Full Text] [Related]
12. [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].
Zhang SW; Xiao SW; Liu CQ; Sun Y; Su X; Li DM; Xu G; Zhu GY; Xu B
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):426-8. PubMed ID: 16188130
[TBL] [Abstract][Full Text] [Related]
13. From gene therapy to virotherapy for ovarian cancer.
Stoff-Khalili MA; Dall P; Curiel DT
Minerva Ginecol; 2004 Dec; 56(6):503-14. PubMed ID: 15729203
[TBL] [Abstract][Full Text] [Related]
14. Replication-selective oncolytic viruses in the treatment of cancer.
Everts B; van der Poel HG
Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
[TBL] [Abstract][Full Text] [Related]
15. Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy.
Hamada K; Kohno S; Iwamoto M; Yokota H; Okada M; Tagawa M; Hirose S; Yamasaki K; Shirakata Y; Hashimoto K; Ito M
Cancer Res; 2003 May; 63(10):2506-12. PubMed ID: 12750273
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated expression of dominant negative c-myb induces apoptosis in head and neck cancer cells and inhibits tumor growth in animal model.
Kim SY; Yang YS; Hong KH; Jang KY; Chung MJ; Lee DY; Lee JC; Yi HK; Nam SY; Hwang PH
Oral Oncol; 2008 Apr; 44(4):383-92. PubMed ID: 17690006
[TBL] [Abstract][Full Text] [Related]
17. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
Su C; Peng L; Sham J; Wang X; Zhang Q; Chua D; Liu C; Cui Z; Xue H; Wu H; Yang Q; Zhang B; Liu X; Wu M; Qian Q
Mol Ther; 2006 May; 13(5):918-27. PubMed ID: 16497559
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers.
Clayman GL; Frank DK; Bruso PA; Goepfert H
Clin Cancer Res; 1999 Jul; 5(7):1715-22. PubMed ID: 10430074
[TBL] [Abstract][Full Text] [Related]
19. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
20. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
